Cart
×
REGENXBIO ANNOUNCES PHASE I/II TRIAL OF RGX-202, A NOVEL GENE THERAPY CANDIDATE FOR DUCHENNE MUSCULAR DYSTROPHY, IS ACTIVE AND RECRUITING PATIENTS
REGENXBIO is recruiting participants aged 4-11 years old for their microdystrophin gene therapy trial, as well as participants aged 0-11 years for an observational study to understand the prevalence of […]
5 Tips for Staying Well During Cold and Flu Season
While COVID-19 is past its peak, the virus has not completely disappeared, and neither have the yearly cold and flu viruses. These viruses hit their peaks between December and February, […]
Entrada Announces Selection of Second Clinical Trial Candidate
Entrada Therapeutics announced the selection of a second clinical candidate, ENTR-601-45, for the potential treatment of people living with Duchenne who are exon 45 skipping amenable. Read more in the […]
Wave Life Sciences announced a positive update from the initial cohort of the Phase 1b/2a study
In December 2022, Wave Life Sciences announced a positive update from the initial cohort of the Phase 1b/2a study of WVE-N531 in three boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping.
Avidity Biosciences Webinar: EXPLORE44
A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and […]
Recovering Ambulation After Lower Extremity Fracture in Duchenne
Historically, a lower extremity fracture for an ambulatory individual with Duchenne likely meant that they would never walk again. Thankfully, for many individuals in recent years, this was not their […]
CureDuchenne Raises More Than $1.5 Million at Eighth Annual Napa in Newport to Help Find a Cure for Duchenne Muscular Dystrophy
Southern California’s Premier Wine Event Brought Together Acclaimed Napa Valley Vintners Under One Roof to Raise Funds for CureDuchenne NEWPORT BEACH Calif., November 10, 2022 – CureDuchenne and Vintner Chair Dana Estates hosted the Eighth […]
Prednisone and deflazacort in Duchenne muscular dystrophy: The Cincinnati Study
This webinar highlights a summary of an article about the Cincinnati study, which was published in the Journal of Comparative Effectiveness Research in January 2020. The study researchers wanted to […]